$23.69
1.04%
Nasdaq, Apr 21, 08:48 pm CET
ISIN
US92686J1060
Symbol
VKTX
Sector
Industry

Viking Therapeutics, Inc. Stock price

$23.94
-5.89 19.75% 1M
-40.68 62.95% 6M
-16.30 40.51% YTD
-42.53 63.98% 1Y
+21.37 831.52% 3Y
+18.32 325.98% 5Y
+14.98 167.19% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.34 1.44%
ISIN
US92686J1060
Symbol
VKTX
Sector
Industry

Key metrics

Market capitalization $2.69b
Enterprise Value $1.79b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.03
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-150.92m
Free Cash Flow (TTM) Free Cash Flow $-87.79m
Cash position $902.61m
EPS (TTM) EPS $-1.01
P/E forward negative
P/S forward 1,720.45
EV/Sales forward 1,143.49
Short interest 27.38%
Show more

Is Viking Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Viking Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Viking Therapeutics, Inc. forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a Viking Therapeutics, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Viking Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.35 0.35
21% 21%
-
-0.35 -0.35
21% 21%
-
- Selling and Administrative Expenses 49 49
33% 33%
-
- Research and Development Expense 102 102
59% 59%
-
-151 -151
50% 50%
-
- Depreciation and Amortization 0.35 0.35
21% 21%
-
EBIT (Operating Income) EBIT -151 -151
50% 50%
-
Net Profit -110 -110
28% 28%
-

In millions USD.

Don't miss a Thing! We will send you all news about Viking Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Viking Therapeutics, Inc. Stock News

Neutral
The Motley Fool
4 days ago
Equity markets have had a rough go of it this year due to President Trump's macroeconomic policies. Though it can be challenging to navigate this environment, one way to make the best of it is to look for terrific stocks to invest in while they are down.
Positive
Seeking Alpha
4 days ago
VKTX's deep selloff from the 2024 heights have been well warranted indeed, given its pre-revenue status and ongoing cash burn, despite the promising GLP-1 candidates. It has also triggered the improved margin of safety and relatively compelling 2030 valuations, despite the recently downgraded forward estimates. This is significantly aided by the improved clarity surrounding VKTX's go-to-market ...
Positive
MarketBeat
5 days ago
Viking Therapeutics Inc. NASDAQ: VKTX has taken investors on a wild ride since the beginning of 2024. At one point, VKTX stock was up 375% from its closing price on January 2, 2024.
More Viking Therapeutics, Inc. News

Company Profile

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Head office United States
CEO Brian Lian
Employees 36
Founded 2012
Website www.vikingtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today